Who is sponsoring NCT03445897?

NCT03445897 is sponsored by Jonathan Berman.

What drugs are being tested in NCT03445897?

Interventions in NCT03445897: miltefosine plus intralesional pentamidine.

What condition does NCT03445897 study?

NCT03445897 studies Leishmaniasis, Cutaneous.

Is NCT03445897 still recruiting?

NCT03445897 is currently completed. Last updated 27 February 2018.

Last reviewed 2018-02-27 · How we verify

NCT03445897

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Miltefosine Plus IL Pentamidine for Bolivian CL

Completed Phase 2 Last updated 27 February 2018

What this trial tests

Phase 2 trial testing miltefosine plus intralesional pentamidine in Leishmaniasis, Cutaneous in 50 participants. Completed in 21 February 2018.

Timeline

31 January 2016

Primary endpoint
31 January 2018

21 February 2018

Quick facts

Lead sponsor	Jonathan Berman
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	31 January 2016
Primary completion	31 January 2018
Estimated completion	21 February 2018

Drugs / interventions tested

miltefosine plus intralesional pentamidine — full drug profile →

Conditions studied

Leishmaniasis, Cutaneous — all drugs for Leishmaniasis, Cutaneous →

Sponsor

Jonathan Berman — full company profile →

Who can join

12 and older, any sex, with Leishmaniasis, Cutaneous. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Bolivian cutaneous leishmaniasis due to Leishmania braziliensis was treated with the combination of miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 ug/mm2 lesion area on days 1, 3, and 5).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Nanotechnological approaches for pentamidine delivery.
Andreana I, Bincoletto V, Milla P, Dosio F, et al · · 2022 · cited 14× · PMID 35217992 · DOI 10.1007/s13346-022-01127-4
Miltefosine Combined with Intralesional Pentamidine for <i>Leishmania braziliensis</i> Cutaneous Leishmaniasis in Bolivia.
Soto J, Soto P, Ajata A, Rivero D, et al · · 2018 · cited 9× · PMID 30255833 · DOI 10.4269/ajtmh.18-0183

Verify or expand the search:

Other recruiting trials for Leishmaniasis, Cutaneous

Currently open trials in the same condition.

NCT07504757 — LEISH-PED: Study on Leishmaniasis in Children · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03445897 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jonathan Berman
Last refreshed: 27 February 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03445897.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing